425 related articles for article (PubMed ID: 18498241)
21. [Drugs for antiretroviral therapy. The costs of HAART].
Jablonowski H
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():21. PubMed ID: 19024911
[No Abstract] [Full Text] [Related]
22. Recent and future therapeutic advances in the management of HIV infection.
Saliba G; Yeni P
Pathol Biol (Paris); 2006 Dec; 54(10):545-50. PubMed ID: 17027195
[TBL] [Abstract][Full Text] [Related]
23. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Ekouevi DK; Coffie PA; Becquet R; Tonwe-Gold B; Horo A; Thiebaut R; Leroy V; Blanche S; Dabis F; Abrams EJ
AIDS; 2008 Sep; 22(14):1815-20. PubMed ID: 18753864
[TBL] [Abstract][Full Text] [Related]
24. Morbidity in HIV-1-Infected children treated or not treated with highly active antiretroviral therapy (HAART), Abidjan, Cote d'Ivoire, 2000-04.
Walenda C; Kouakoussui A; Rouet F; Wemin L; Anaky MF; Msellati P
J Trop Pediatr; 2009 Jun; 55(3):170-6. PubMed ID: 19066169
[TBL] [Abstract][Full Text] [Related]
25. HIV and hepatitis C coinfection.
Matthews GV; Dore GJ
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1000-8. PubMed ID: 18707597
[TBL] [Abstract][Full Text] [Related]
26. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
27. Influence of highly active antiretroviral treatment (HAART) on risk factors for vertical HIV transmission.
Garcia-Tejedor A; Maiques V; Perales A; Lopez-Aldeguer J
Acta Obstet Gynecol Scand; 2009; 88(8):882-7. PubMed ID: 19557554
[TBL] [Abstract][Full Text] [Related]
28. Optimal drug treatment regimens for HIV depend on adherence.
Krakovska O; Wahl LM
J Theor Biol; 2007 Jun; 246(3):499-509. PubMed ID: 17320115
[TBL] [Abstract][Full Text] [Related]
29. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad.
Koyalta D; Charpentier C; Beassamda J; Rey E; Si-Mohamed A; Djemadji-Oudjeil N; Bélec L
Clin Infect Dis; 2009 Jul; 49(1):155-9. PubMed ID: 19480574
[TBL] [Abstract][Full Text] [Related]
30. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
[TBL] [Abstract][Full Text] [Related]
31. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
[TBL] [Abstract][Full Text] [Related]
32. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P
HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761
[TBL] [Abstract][Full Text] [Related]
33. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
34. The economics of effective AIDS treatment in Thailand.
Over M; Revenga A; Masaki E; Peerapatanapokin W; Gold J; Tangcharoensathien V; Thanprasertsuk S
AIDS; 2007 Jul; 21 Suppl 4():S105-16. PubMed ID: 17620745
[TBL] [Abstract][Full Text] [Related]
35. Challenges of adherence management in human immunodeficiency virus pharmacotherapy.
Park-Wyllie LY; Phillips EJ
Can J Clin Pharmacol; 2003; 10(4):189-95. PubMed ID: 14712324
[TBL] [Abstract][Full Text] [Related]
36. Baseline HIV RNA and the when to start question: time to stop asking this question?
Mussini C
AIDS; 2006 May; 20(8):1197-8. PubMed ID: 16691072
[No Abstract] [Full Text] [Related]
37. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda.
Kent DM; McGrath D; Ioannidis JP; Bennish ML
Clin Infect Dis; 2003 Jul; 37(Suppl 1):S13-24. PubMed ID: 12822128
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral drug development: the challenge of cost and access.
Dunne M
AIDS; 2007 Jul; 21 Suppl 4():S73-9. PubMed ID: 17620756
[TBL] [Abstract][Full Text] [Related]
39. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
40. From directly observed therapy to accompagnateurs: enhancing AIDS treatment outcomes in Haiti and in Boston.
Behforouz HL; Farmer PE; Mukherjee JS
Clin Infect Dis; 2004 Jun; 38 Suppl 5():S429-36. PubMed ID: 15156434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
